[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338791-105":59,"doc-detail-338791-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mechanisms-of-immune-checkpoint-inhibitors-insights-into-the-regulation-of-circular-rnas-involved-in-cancer-hallmarks-review-article","Mechanisms of immune checkpoint inhibitors - insights into the regulation of circular RNAS involved in cancer hallmarks - Review Article","","Cancer therapy is constrained by limited effectiveness of current treatments, especially in advanced disease. Immune checkpoint inhibitors (ICIs) activate antitumor immunity by blocking immune checkpoint molecules, including anti-PD-1/PD-L1 drugs, but overall response rates remain low and both primary and acquired resistance restrict clinical benefit. Immune-related adverse events and hyperprogression further complicate use. This review systematically summarizes how circular RNAs (circRNAs) regulate immune checkpoints and influence cancer hallmarks in a manner that may shape ICI responses and resistance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mechanisms-of-immune-checkpoint-inhibitors-insights-into-the-regulation-of-circular-rnas-involved-in-cancer-hallmarks-review-article/338791/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mechanisms-of-immune-checkpoint-inhibitors-insights-into-the-regulation-of-circular-rnas-involved-in-cancer-hallmarks-review-article/338791.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are immune checkpoint inhibitors not effective for all cancer patients?","Question",{"text":113,"@type":114},"Overall response rates are relatively low for most cancer types, and primary plus acquired resistance limit sustained clinical benefit even when biomarkers such as PD-L1 are considered.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do immune checkpoint inhibitors modulate immune responses?",{"text":118,"@type":114},"They target immunosuppressive immune checkpoint molecules on immune cells, regulating immune activation and helping avoid autoimmune responses while enabling antitumor immunity.",{"name":120,"@type":111,"acceptedAnswer":121},"What roles do circular RNAs (circRNAs) play in relation to immune checkpoints?",{"text":122,"@type":114},"circRNAs are discussed as emerging modulators involved in cancer hallmarks and as regulatory elements that can impact immune checkpoint activity, thereby shaping tumor immune microenvironment and ICI effects and resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338791,1790156801,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","[www.nature.com/cddis](www.nature.com/cddis)  \nREVIEW ARTICLE OPEN   \nMechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks  \nLingjiao Meng1,2,6, Haotian Wu3,4,6, Jiaxiang Wu3,4,6, Ping’an Ding3,4,6, Jinchen He3,4, Meixiang Sang2,5 ✉ and Lihua Liu 1 ✉  \n© The Author(s) 2024  \n\n|  |  |  |\n| --- | --- | --- |\n|  | Current treatment strategies for cancer, especially advanced cancer, are limited and unsatisfactory. One of the most substantial advances in cancer therapy, in the last decades, was the discovery of a new layer of immunotherapy approach, immune checkpoint inhibitors (ICIs), which can speciﬁcally activate immune cells by targeting immune checkpoints. Immune checkpoints are a type of immunosuppressive molecules expressed on immune cells, which can regulate the degree of immune activation and avoid autoimmune responses. ICIs, such as anti-PD-1/PD-L1 drugs, has shown inspiring efﬁcacy and broad applicability across various cancers. Unfortunately, not all cancer patients beneﬁt remarkably from ICIs, and the overall response rates to ICIs remain relatively low for most cancer types. Moreover, the primary and acquired resistance to ICIs pose serious challenges to the clinical application of cancer immunotherapy. Thus, a deeper understanding of the molecular biological properties and regulatory mechanisms of immune checkpoints is urgently needed to improve clinical options for current therapies. Recently, circular RNAs (circRNAs) have attracted increasing attention, not only due to their involvement in various aspects of cancer hallmarks, but also for their impact on immune checkpoints in shaping the tumor immune microenvironment. In this review, we systematically summarize the current status of immune checkpoints in cancer and the existing regulatory roles of circRNAs on immune checkpoints. Meanwhile, we also aim to settle the issue in an evidence-oriented manner that circRNAs involved in cancer hallmarks regulate the effects and |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | resistance of ICIs by targeting immune checkpoints. |  |\n|  |  |  |\n|  |  |  |\n|  | Cell Death and Disease (2024)15:3; [https://doi.org/10.1038/s41419-023-06389-5](https://doi.org/10.1038/s41419-023-06389-5) |  |\n|  |  |  |\n\nFACTS  \n● ICIs has achieved prominent efﬁcacy in many types of cancer and revolutionized the status of cancer immunotherapy.  \n● Primary and acquired resistance limit the clinical application of ICIs in cancer immunotherapy.  \n● CircRNAs as emerging modulators of various cancer hallmarks are associated with the regulation of ICIs by targeting immune checkpoints.  \nQUESTIONS  \n● Can circRNAs directly serve as immune checkpoints to regulate immune responses against cancer cells?  \n● Can circRNAs involved in cancer hallmarks such as proliferation and cell death mediate ICIs resistance?  \n● Is resistance to ICIs mediated by circRNAs in tumor cells or immune cells, or a combination of both?  \n● Can synthetic circRNAs regulate the cascades involved in  \nimmune checkpoint pathways and serve as new potential cancer immunotherapy regimens?  \nINTRODUCTION  \nCancer immunotherapy with ICIs by inhibition of negative immune regulation to enhance immune activity against cancer cells, which won the 2018 Nobel Prize in Physiology or Medicine, has revolutionized the treatment dilemma of various human malignancies [1–4]. The ﬁrst immune checkpoint inhibitor approved by FDA named lpilimumab that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to potentiate the T cell-mediated antitumor immune response, have remarkably improved the overall survival of metastatic melanoma patients [5–8]. Subsequently, the FDA approved programmed cell death protein 1 (PD-1) inhibitor nivolumab for the treatment of advanced melanoma due to its favorable overall survival, durable tumor remissio","cbCaipgoMDbrEgdm","https://ap.wps.com/l/cbCaipgoMDbrEgdm","pdf",3524601,26,"English","# Introduction\n## Immune checkpoint inhibitors and clinical limitations\n## Immune checkpoint regulation and resistance\n# Facts and Questions\n## Facts about ICIs and circRNAs\n## Key research questions","[{\"question\":\"Why are immune checkpoint inhibitors not effective for all cancer patients?\",\"answer\":\"Overall response rates are relatively low for most cancer types, and primary plus acquired resistance limit sustained clinical benefit even when biomarkers such as PD-L1 are considered.\"},{\"question\":\"How do immune checkpoint inhibitors modulate immune responses?\",\"answer\":\"They target immunosuppressive immune checkpoint molecules on immune cells, regulating immune activation and helping avoid autoimmune responses while enabling antitumor immunity.\"},{\"question\":\"What roles do circular RNAs (circRNAs) play in relation to immune checkpoints?\",\"answer\":\"circRNAs are discussed as emerging modulators involved in cancer hallmarks and as regulatory elements that can impact immune checkpoint activity, thereby shaping tumor immune microenvironment and ICI effects and resistance.\"}]","Mechanisms of immune checkpoint inhibitors - insights into the regulation of circular RNAS involved in cancer hallmarks - Review Article | PDF",1790025673,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cafabb95e94a0cbaa0744d8f67b094db.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef607dfc328551d3fb07f9b213248f33.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc2fc3e356808faffed2602f4bdfbc43.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab564c3fe971fbb38945d5770ce5ab19.webp",980,1301]